Press Releases Press Releases Year: - Any -201820172016201520142013 May 08, 2018 Summary ToggleMelinta Therapeutics Reports First Quarter 2018 Financial Results May 08, 2018 Summary ToggleMelinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting May 07, 2018 Summary ToggleMelinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria April 27, 2018 Summary ToggleMelinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 April 23, 2018 Summary ToggleMelinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations April 23, 2018 Summary ToggleMelinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018 April 16, 2018 Summary ToggleMelinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018 March 14, 2018 Summary ToggleMelinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference March 13, 2018 Summary ToggleMelinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather March 13, 2018 Summary ToggleMelinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
Press Releases Year: - Any -201820172016201520142013 May 08, 2018 Summary ToggleMelinta Therapeutics Reports First Quarter 2018 Financial Results May 08, 2018 Summary ToggleMelinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting May 07, 2018 Summary ToggleMelinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria April 27, 2018 Summary ToggleMelinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 April 23, 2018 Summary ToggleMelinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations April 23, 2018 Summary ToggleMelinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018 April 16, 2018 Summary ToggleMelinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018 March 14, 2018 Summary ToggleMelinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference March 13, 2018 Summary ToggleMelinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather March 13, 2018 Summary ToggleMelinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
